Generating induced pluripotent stem cells for multiple sclerosis therapy

Regenerative Medicine

Volumn 9, Issue 6, 2014, Pages 709-711

  Fossati, Valentina ^a   Douvaras, Panagiotis ^a  

^a New York Stem Cell Foundation Laboratory   (United States)

Author keywords

iPSC; multiple sclerosis; neurodegeneration; neuroprotection; oligodendrocyte progenitor cells; re myelination

Indexed keywords

AUTOLOGOUS STEM CELL TRANSPLANTATION; EDITORIAL; HUMAN; MULTIPLE SCLEROSIS; NERVE CELL DIFFERENTIATION; NERVE DEGENERATION; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; PLURIPOTENT STEM CELL; REMYELINIZATION; STEM CELL CULTURE; STEM CELL TRANSPLANTATION; THERAPY EFFECT; CELL DIFFERENTIATION; CYTOLOGY; PHYSIOLOGY; REGENERATION;

CELL DIFFERENTIATION; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MULTIPLE SCLEROSIS; REGENERATION;

EID: 84913610932     PISSN: 17460751     EISSN: 1746076X     Source Type: Journal    
DOI: 10.2217/rme.14.63     Document Type: Editorial

References (17)

1. Inoue H, Nagata N, Kurokawa H, Yamanaka S. iPS cells: a game changer for future medicine. EMBO J. 33 (5), 409-417 (2014).
2. Trapp BD, Nave KA. Multiple sclerosis: an immune disease or neurodegenerative disorder? Annu. Rev. Neurosci. 31, 247-269 (2008).
3. Stys PK, Zamponi GW, van Minnen J, Geurts JJ. Will the real multiple sclerosis please stand up? Nat. Rev. Neurosci. 13 (7), 507-514 (2012).
4. Kriks S, Shim JW, Piao J et al. Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease. Nature 480 (7378), 547-551 (2011).
5. Liu Y, Liu H, Sauvey C, Yao L, Zarnowska ED, Zhang SC. Directed differentiation of forebrain GABA interneurons from human pluripotent stem cells. Nat. Protoc. 8 (9), 1670-1679 (2013).
6. Israel MA, Yuan SH, Bardy C et al. Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells. Nature 482 (73840), 216-220 (2012).
7. Brennand KJ, Simone A, Jou J et al. Modelling schizophrenia using human induced pluripotent stem cells. Nature 473 (7346), 221-225 (2011).
8. Dutta R, McDonough J, Yin X et al. Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Ann. Neurol. 59 (3), 478-489 (2006).
9. Yang YM, Gupta SK, Kim KJ et al. A small molecule screen in stem-cell-derived motor neurons identifies a kinase inhibitor as a candidate therapeutic for ALS. Cell Stem Cell 12 (6), 713-726 (2013).
10. Mi S, Miller RH, Lee X et al. LINGO-1 negatively regulates myelination by oligodendrocytes. Nat. Neurosci. 8 (6), 745-751 (2005).
11. Fancy SP, Baranzini SE, Zhao C et al. Dysregulation of the Wnt pathway inhibits timely myelination and remyelination in the mammalian CNS. Genes Dev. 23 (13), 1571-1585 (2009).
12. Mei F, Fancy SP, Shen YA et al. Micropillar arrays as a highthroughput screening platform for therapeutics in multiple sclerosis. Nat. Med. 20 (8), 954-960 (2014).
13. Douvaras P, Wang J, Zimmer M et al. Efficient generation of myelinating oligodendrocytes from primary progressive multiple sclerosis patients by induced pluripotent stem cells. Stem Cell Reports 3 (2), 250-259 (2014).
14. Wang S, Bates J, Li X et al. Human iPSC-derived oligodendrocyte progenitor cells can myelinate and rescue a mouse model of congenital hypomyelination. Cell Stem Cell 12 (2), 252-264 (2013).
15. Terrenoire C, Wang K, Tung KW et al. Induced pluripotent stem cells used to reveal drug actions in a long QT syndrome family with complex genetics. J. Gen. Physiol. 141 (1), 61-72 (2013).
16. Reinhardt P, Schmid B, Burbulla LF et al. Genetic correction of a LRRK2 mutation in human iPSCs links parkinsonian neurodegeneration to ERK-dependent changes in gene expression. Cell Stem Cell 12 (3), 354-367 (2013).
17. Kondo T, Asai M, Tsukita K et al. Modeling Alzheimer's disease with iPSCs reveals stress phenotypes associated with intracellular Aβ and differential drug responsiveness. Cell Stem Cell 12 (4), 487-496 (2013).